{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:53:05Z","timestamp":1781589185399,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatocellular carcinoma (HCC) frequently arises from uncontrolled proliferation of hepatocyte epithelium, a process potently driven by the transcriptional regulator yes-associated protein (YAP). Although 1,25(OH)\u2082D\u2083, the active form of vitamin D, exerts established anti-proliferative effects through its receptor (VDR), the specific roles of its two principal isoforms, VDRA and VDRB1, have remained largely undefined. Clinical analysis of the TCGA-LIHC database identified high VDRB1 and low VDRA expression as robust independent risk factors for poor prognosis, suggesting their divergent impacts on HCC progression. Here, we demonstrated that 1,25(OH)\u2082D\u2083 induced coordinate expression of both VDR isoforms in HCC cells, activated divergent transcriptional programs, particularly concerning the regulation of YAP target genes. Crucially, functional overexpression assays revealed that VDRA, but not VDRB1, potently inhibited YAP activation, an effect synergistically augmented by combined treatment with 1,25(OH)\u2082D\u2083. This regulatory axis was further substantiated by endogenous VDR silencing, while the VDRA-mediated repression of YAP signaling was substantially abrogated by constitutively active YAP-5SA. Functionally, VDRA impaired the proliferation and colony-forming capacity of HCC cells\u2014an inhibitory action significantly rescued by YAP-5SA overexpression\u2014whereas VDR knockdown promoted cell growth. Mechanistically, VDRA efficiently translocated to the nucleus to restrict YAP nuclear localization, while 1,25(OH)\u2082D\u2083-treated VDRB1 formed perinuclear condensates that failed to enter the nucleus. To confirm these mechanisms, we employed patient-derived HCC organoids (validated by H&amp;E, RNA-seq, and WES). Subcutaneous engraftment demonstrated that VDRA overexpression, but not VDRB1, profoundly suppressed tumor growth by attenuating YAP activity. Taken together, our findings establish the VDRA isoform as the primary mediator of 1,25(OH)\u2082D\u2083-induced tumor suppression in HCC. By demonstrating that VDRA curtails hepatocarcinogenesis specifically by restricting YAP nuclear localization, this study delineates a novel isoform-specific mechanism within the vitamin D signaling axis, nominating VDRA as a promising biomarker and therapeutic target for YAP-driven liver cancer.<\/jats:p>","DOI":"10.1038\/s41419-026-08792-0","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:08:16Z","timestamp":1777475296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vitamin D receptor isoform VDRA suppresses hepatocellular tumorigenesis by restricting YAP nuclear localization"],"prefix":"10.1038","volume":"17","author":[{"given":"Lizhi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RuoYa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0404-7709","authenticated-orcid":false,"given":"Bingyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8398-8282","authenticated-orcid":false,"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"8792_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301\u201314.","journal-title":"Lancet"},{"key":"8792_CR2","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1093\/jnci\/djab131","volume":"113","author":"F Islami","year":"2021","unstructured":"Islami F, Ward EM, Sung H, Cronin KA, Tangka FKL, Sherman RL, et al. Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics. J Natl Cancer Inst. 2021;113:1648\u201369.","journal-title":"J Natl Cancer Inst"},{"key":"8792_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7:6.","journal-title":"Nat Rev Dis Prim"},{"key":"8792_CR4","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"A-L Cheng","year":"2022","unstructured":"Cheng A-L, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862\u201373.","journal-title":"J Hepatol"},{"key":"8792_CR5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"8792_CR6","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389:2492\u2013502.","journal-title":"Lancet"},{"key":"8792_CR7","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1172\/JCI59261","volume":"121","author":"Y Malato","year":"2011","unstructured":"Malato Y, Naqvi S, Sch\u00fcrmann N, Ng R, Wang B, Zape J, et al. Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Investig. 2011;121:4850\u201360.","journal-title":"J Clin Investig"},{"key":"8792_CR8","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.cell.2014.03.060","volume":"157","author":"D Yimlamai","year":"2014","unstructured":"Yimlamai D, Christodoulou C, Galli GG, Yanger K, Pepe-Mooney B, Gurung B, et al. Hippo pathway activity influences liver cell fate. Cell. 2014;157:1324\u201338.","journal-title":"Cell"},{"key":"8792_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41580-018-0086-y","volume":"20","author":"IM Moya","year":"2019","unstructured":"Moya IM, Halder G. Hippo-YAP\/TAZ signalling in organ regeneration and regenerative medicine. Nat Rev Mol Cell Biol. 2019;20:211\u201326.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8792_CR10","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1158\/0008-5472.CAN-15-0291","volume":"75","author":"H Hayashi","year":"2015","unstructured":"Hayashi H, Higashi T, Yokoyama N, Kaida T, Sakamoto K, Fukushima Y, et al. An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression. Cancer Res. 2015;75:4985\u201397.","journal-title":"Cancer Res"},{"key":"8792_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41575-021-00571-w","volume":"19","author":"JO Russell","year":"2022","unstructured":"Russell JO, Camargo FD. Hippo signalling in the liver: role in development, regeneration and disease. Nat Rev Gastroenterol Hepatol. 2022;19:297\u2013312.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8792_CR12","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.cell.2006.05.030","volume":"125","author":"L Zender","year":"2006","unstructured":"Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006;125:1253\u201367.","journal-title":"Cell"},{"key":"8792_CR13","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2007.07.019","volume":"130","author":"J Dong","year":"2007","unstructured":"Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130:1120\u201333.","journal-title":"Cell"},{"key":"8792_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jsbmb.2017.07.003","volume":"177","author":"A Aggarwal","year":"2018","unstructured":"Aggarwal A, Feldman D, Feldman BJ. Identification of tumor-autonomous and indirect effects of vitamin D action that inhibit breast cancer growth and tumor progression. J Steroid Biochem Mol Biol. 2018;177:155\u20138.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"8792_CR15","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1158\/1535-7163.MCT-15-0066","volume":"14","author":"Y Jeong","year":"2015","unstructured":"Jeong Y, Swami S, Krishnan AV, Williams JD, Martin S, Horst RL, et al. Inhibition of mouse breast tumor-initiating cells by calcitriol and dietary Vitamin D. Mol Cancer Ther. 2015;14:1951\u201361.","journal-title":"Mol Cancer Ther"},{"key":"8792_CR16","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1158\/1078-0432.CCR-23-0447","volume":"29","author":"Q-L Wang","year":"2023","unstructured":"Wang Q-L, Ma C, Yuan C, Shi Q, Wolpin BM, Zhang Y, et al. Plasma 25-Hydroxyvitamin D levels and survival in Stage III Colon Cancer: Findings from CALGB\/SWOG 80702 (Alliance). Clin Cancer Res. 2023;29:2621\u201330.","journal-title":"Clin Cancer Res"},{"key":"8792_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(85)91082-7","volume":"1","author":"C Garland","year":"1985","unstructured":"Garland C, Shekelle RB, Barrett-Connor E, Criqui MH, Rossof AH, Paul O. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet. 1985;1:307\u20139.","journal-title":"Lancet"},{"key":"8792_CR18","doi-asserted-by":"crossref","unstructured":"Kim H, Lipsyc-Sharf M, Zong X, Wang X, Hur J, Song M, et al. Total Vitamin D intake and risks of early-onset colorectal cancer and precursors. Gastroenterology 2021;161:1208\u201317.e9.","DOI":"10.1053\/j.gastro.2021.07.002"},{"key":"8792_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1158\/1055-9965.EPI-15-0991","volume":"25","author":"AM Mondul","year":"2016","unstructured":"Mondul AM, Weinstein SJ, Moy KA, M\u00e4nnist\u00f6 S, Albanes D. Circulating 25-Hydroxyvitamin D and Prostate Cancer Survival. Cancer Epidemiol Biomark Prev. 2016;25:665\u20139.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"8792_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1017\/S0007114515004353","volume":"115","author":"M Deschasaux","year":"2016","unstructured":"Deschasaux M, Souberbielle J-C, Latino-Martel P, Sutton A, Charnaux N, Druesne-Pecollo N, et al. A prospective study of plasma 25-hydroxyvitamin D concentration and prostate cancer risk. Br J Nutr. 2016;115:305\u201314.","journal-title":"Br J Nutr"},{"key":"8792_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1126\/science.adh7954","volume":"384","author":"E Giampazolias","year":"2024","unstructured":"Giampazolias E, Pereira da Costa M, Lam KC, Lim KHJ, Cardoso A, Piot C, et al. Vitamin D regulates microbiome-dependent cancer immunity. Sci (N Y, NY). 2024;384:428\u201337.","journal-title":"Sci (N Y, NY)"},{"key":"8792_CR22","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"EASL-EORTC Clinical Practice Guidelines.","year":"2012","unstructured":"EASL-EORTC Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2012;56:908\u201343.","journal-title":"J Hepatol"},{"key":"8792_CR23","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/bjc.2013.546","volume":"109","author":"JB Wang","year":"2013","unstructured":"Wang JB, Abnet CC, Chen W, Dawsey SM, Fan JH, Yin LY, et al. Association between serum 25(OH) vitamin D, incident liver cancer and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study. Br J Cancer. 2013;109:1997\u20132004.","journal-title":"Br J Cancer"},{"key":"8792_CR24","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/hep.27079","volume":"60","author":"V Fedirko","year":"2014","unstructured":"Fedirko V, Duarte-Salles T, Bamia C, Trichopoulou A, Aleksandrova K, Trichopoulos D, et al. Prediagnostic circulating vitamin D levels and risk of hepatocellular carcinoma in European populations: a nested case-control study. Hepatology. 2014;60:1222\u201330.","journal-title":"Hepatology"},{"key":"8792_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.31013","volume":"72","author":"A-P Fang","year":"2020","unstructured":"Fang A-P, Long J-A, Zhang Y-J, Liu Z-Y, Li Q-J, Zhang D-M, et al. Serum bioavailable, rather than total, 25-hydroxyvitamin D levels are associated with hepatocellular carcinoma survival. Hepatology. 2020;72:169\u201382.","journal-title":"Hepatology"},{"key":"8792_CR26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jhep.2013.03.024","volume":"59","author":"E Tr\u00e9po","year":"2013","unstructured":"Tr\u00e9po E, Ouziel R, Pradat P, Momozawa Y, Quertinmont E, Gervy C, et al. Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver disease. J Hepatol. 2013;59:344\u201350.","journal-title":"J Hepatol"},{"key":"8792_CR27","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.2174\/09298673113209990248","volume":"20","author":"J Guo","year":"2013","unstructured":"Guo J, Ma Z, Ma Q, Wu Z, Fan P, Zhou X, et al. 1, 25(OH)\u2082D\u2083 inhibits hepatocellular carcinoma development through reducing secretion of inflammatory cytokines from immunocytes. Curr Med Chem. 2013;20:4131\u201341.","journal-title":"Curr Med Chem"},{"key":"8792_CR28","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.biopha.2018.08.153","volume":"107","author":"J Xu","year":"2018","unstructured":"Xu J, Wang Y, Zhang Y, Dang S, He S. Astemizole promotes the anti-tumor effect of vitamin D through inhibiting miR-125a-5p-mediated regulation of VDR in HCC. Biomed Pharmacother. 2018;107:1682\u201391.","journal-title":"Biomed Pharmacother"},{"key":"8792_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2019.105524","volume":"197","author":"Q Wu","year":"2020","unstructured":"Wu Q, Wang X, Pham K, Luna A, Studzinski GP, Liu C. Enhancement of sorafenib-mediated death of Hepatocellular carcinoma cells by Carnosic acid and Vitamin D2 analog combination. J Steroid Biochem Mol Biol. 2020;197:105524.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"8792_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jsbmb.2018.08.002","volume":"183","author":"J Wang","year":"2018","unstructured":"Wang J, Chen Y, Mo P-L, Wei Y-J, Liu K-C, Zhang Z-G, et al. 1\u03b1,25-Dihydroxyvitamin D3 inhibits aflatoxin B1-induced proliferation and dedifferentiation of hepatic progenitor cells by regulating PI3K\/Akt and Hippo pathways. J Steroid Biochem Mol Biol. 2018;183:228\u201337.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"8792_CR31","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.ccell.2016.09.004","volume":"30","author":"A Duran","year":"2016","unstructured":"Duran A, Hernandez ED, Reina-Campos M, Castilla EA, Subramaniam S, Raghunandan S, et al. p62\/SQSTM1 by binding to Vitamin D receptor inhibits hepatic stellate cell activity, fibrosis, and liver cancer. Cancer Cell. 2016;30:595\u2013609.","journal-title":"Cancer Cell"},{"key":"8792_CR32","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/hepr.12302","volume":"44","author":"JP Hamilton","year":"2014","unstructured":"Hamilton JP, Potter JJ, Koganti L, Meltzer SJ, Mezey E. Effects of vitamin D3 stimulation of thioredoxin-interacting protein in hepatocellular carcinoma. Hepatol Res. 2014;44:1357\u201366.","journal-title":"Hepatol Res"},{"key":"8792_CR33","doi-asserted-by":"publisher","first-page":"991","DOI":"10.31557\/APJCP.2021.22.4.991","volume":"22","author":"Z Yi","year":"2021","unstructured":"Yi Z, Wang L, Tu X. Effect of Vitamin D deficiency on liver cancer risk: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2021;22:991\u20137.","journal-title":"Asian Pac J Cancer Prev"},{"key":"8792_CR34","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1210\/mend.15.9.0693","volume":"15","author":"KL Sunn","year":"2001","unstructured":"Sunn KL, Cock TA, Crofts LA, Eisman JA, Gardiner EM. Novel N-terminal variant of human VDR. Mol Endocrinol. 2001;15:1599\u2013609.","journal-title":"Mol Endocrinol"},{"key":"8792_CR35","doi-asserted-by":"crossref","unstructured":"Esteban LM, Fong C, Amr D, Cock T-A, Allison SJ, Flanagan JL, et al. Promoter-, cell-, and ligand-specific transactivation responses of the VDRB1 isoform. Biochem Biophys Res Commun 2005;334:9\u201315.","DOI":"10.1016\/j.bbrc.2005.06.054"},{"key":"8792_CR36","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1042\/BJ20042040","volume":"388","author":"KL Sunn","year":"2005","unstructured":"Sunn KL, Eisman JA, Gardiner EM, Jans DA. FRAP analysis of nucleocytoplasmic dynamics of the vitamin D receptor splice variant VDRB1: preferential targeting to nuclear speckles. Biochem J. 2005;388:509\u201314.","journal-title":"Biochem J"},{"key":"8792_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.130405","volume":"263","author":"P Wang","year":"2024","unstructured":"Wang P, Nie J, Li J, Ye C, Chen J, Zhang Z, et al. VDRA downregulate \u03b2-catenin\/Smad3 and DNA damage and repair associated with improved prognosis in ccRCC patients. Int J Biol Macromol. 2024;263:130405.","journal-title":"Int J Biol Macromol"},{"key":"8792_CR38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fphys.2014.00137","volume":"5","author":"J van de Peppel","year":"2014","unstructured":"van de Peppel J, van Leeuwen JP. Vitamin D and gene networks in human osteoblasts. Front Physiol. 2014;5:137.","journal-title":"Front Physiol"},{"key":"8792_CR39","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.cell.2013.03.028","volume":"153","author":"N Ding","year":"2013","unstructured":"Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, et al. A vitamin D receptor\/SMAD genomic circuit gates hepatic fibrotic response. Cell. 2013;153:601\u201313.","journal-title":"Cell"},{"key":"8792_CR40","doi-asserted-by":"publisher","first-page":"10529","DOI":"10.1073\/pnas.95.18.10529","volume":"95","author":"LA Crofts","year":"1998","unstructured":"Crofts LA, Hancock MS, Morrison NA, Eisman JA. Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. Proc Natl Acad Sci USA. 1998;95:10529\u201334.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8792_CR41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jsbmb.2004.03.078","volume":"89-90","author":"EM Gardiner","year":"2004","unstructured":"Gardiner EM, Esteban LM, Fong C, Allison SJ, Flanagan JL, Kouzmenko AP, et al. Vitamin D receptor B1 and exon 1d: functional and evolutionary analysis. J Steroid Biochem Mol Biol. 2004;89-90:233\u20138.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"8792_CR42","doi-asserted-by":"publisher","first-page":"35390","DOI":"10.18632\/oncotarget.15697","volume":"8","author":"O Zenata","year":"2017","unstructured":"Zenata O, Vrzal R. Fine tuning of vitamin D receptor (VDR) activity by post-transcriptional and post-translational modifications. Oncotarget. 2017;8:35390\u2013402.","journal-title":"Oncotarget"},{"key":"8792_CR43","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1002\/cncr.24495","volume":"115","author":"MZ Xu","year":"2009","unstructured":"Xu MZ, Yao T-J, Lee NPY, Ng IOL, Chan Y-T, Zender L, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009;115:4576\u201385.","journal-title":"Cancer"},{"key":"8792_CR44","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-15-1447","volume":"22","author":"BH Sohn","year":"2016","unstructured":"Sohn BH, Shim J-J, Kim S-B, Jang KY, Kim SM, Kim JH, et al. Inactivation of Hippo pathway is significantly associated with poor prognosis in hepatocellular carcinoma. Clin Cancer Res. 2016;22:1256\u201364.","journal-title":"Clin Cancer Res"},{"key":"8792_CR45","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1126\/science.aav0173","volume":"363","author":"CK Lee","year":"2019","unstructured":"Lee CK, Jeong SH, Jang C, Bae H, Kim YH, Park I, et al. Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. Science. 2019;363:644\u20139.","journal-title":"Science"},{"key":"8792_CR46","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fphar.2020.00200","volume":"11","author":"X Wang","year":"2020","unstructured":"Wang X, Wang G, Qu J, Yuan Z, Pan R, Li K. Calcipotriol Inhibits NLRP3 Signal Through YAP1 activation to alleviate cholestatic liver injury and fibrosis. Front Pharm. 2020;11:200.","journal-title":"Front Pharm"},{"key":"8792_CR47","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/path.5750","volume":"255","author":"J Xie","year":"2021","unstructured":"Xie J, Fan Y, Jia R, Yang F, Ma L, Li L. Yes-associated protein regulates the hepatoprotective effect of vitamin D receptor activation through promoting adaptive bile duct remodeling in cholestatic mice. J Pathol. 2021;255:205\u2013218.","journal-title":"J Pathol"},{"key":"8792_CR48","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/1541-7786.MCR-21-0425","volume":"20","author":"Y Ladumor","year":"2022","unstructured":"Ladumor Y, Seong BKA, Hallett R, Valencia-Sama I, Adderley T, Wang Y, et al. Vitamin D receptor activation attenuates Hippo pathway effectors and cell survival in metastatic neuroblastoma. Mol Cancer Res. 2022;20:895\u2013908.","journal-title":"Mol Cancer Res"},{"key":"8792_CR49","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.21873\/anticanres.13478","volume":"39","author":"D Skrajnowska","year":"2019","unstructured":"Skrajnowska D, Bobrowska-Korczak B. Potential molecular mechanisms of the anti-cancer activity of Vitamin D. Anticancer Res. 2019;39:3353\u201363.","journal-title":"Anticancer Res"},{"key":"8792_CR50","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2020.04.018","volume":"181","author":"S Basu","year":"2020","unstructured":"Basu S, Mackowiak SD, Niskanen H, Knezevic D, Asimi V, Grosswendt S, et al. Unblending of transcriptional condensates in human repeat expansion disease. Cell. 2020;181:1062.","journal-title":"Cell"},{"key":"8792_CR51","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/j.cell.2018.10.042","volume":"175","author":"A Boija","year":"2018","unstructured":"Boija A, Klein IA, Sabari BR, Dall\u2019Agnese A, Coffey EL, Zamudio AV, et al. Transcription factors activate genes through the phase-separation capacity of their activation domains. Cell. 2018;175:1842.","journal-title":"Cell"},{"key":"8792_CR52","first-page":"323","volume":"25","author":"X Hu","year":"2023","unstructured":"Hu X, Wu X, Berry K, Zhao C, Xin D, Ogurek S, et al. Nuclear condensates of YAP fusion proteins alter transcription to drive ependymoma tumourigenesis. Nat Cell Biol. 2023;25:323\u201336.","journal-title":"Nat Cell Biol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08792-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08792-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08792-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:09:40Z","timestamp":1781586580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08792-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8792"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08792-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study protocol, involving the collection and use of patient tissues, was reviewed and approved by the Ethics Committee of Biomedical Research, Fujian Medical University (Approval No. FUYI-ETHICS-2025-57), and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participating patients prior to their inclusion in the study. Additionally, data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were utilized, which are publicly available and were accessed in compliance with their respective data policies. The original studies contributing to these public databases had already secured ethical approval and patient consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"573"}}